D6014C00006: A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of AZD1775 on the Pharmacokinetics of Substrates for CYP3A, CYP2C19, CYP1A2 and to Provide Data on the Effect of AZD1775 on QT Interval in Patients With Advanced Solid Tumours

February 24, 2019
https://clinicaltrials.gov/ct2/results?id=NCT03333824
Solid Tumors, Cancer - Ovarian
Principal Investigator: Ding Wang, MD
Cancer, Phase 1, Phase I, Solid Tumors, Advanced Solid Tumors, 
Open